ArticleRevista da Associacao Medica Brasileira (1992)2025
Investigation of the cardiac impacts of endothelial PAS domain-containing protein 1 and ghrelin in patients with systemic lupus erythematosus.
Article in Revista da Associacao Medica Brasileira (1992), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prognostic Role of Copeptin, H-FABP, and TTE in Pulmonary Embolism in the Emergency Department.Emergency medicine international · 2026Article
- Comment on: "The role of EPAS-1 and ghrelin in right ventricular dysfunction in systemic lupus erythematosus".Revista da Associacao Medica Brasileira (1992) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveSystemic lupus erythematosus is a chronic autoimmune disease with significant cardiac manifestations, including right ventricular dysfunction and pulmonary hypertension. This study aims to explore the relationship between endothelial PAS domain-containing protein 1 and ghrelin levels with right ventricular function in patients with systemic lupus erythematosus and assess their potential as biomarkers for cardiac involvement.
methodsA prospective study was conducted involving 34 patients with systemic lupus erythematosus and 35 healthy controls. Echocardiographic parameters were recorded. Serum levels of endothelial PAS domain-containing protein 1 and ghrelin were measured using enzyme-linked immunosorbent assay. Statistical analyses included comparisons between groups and correlations between biomarkers and echocardiographic parameters.
resultsPatients with systemic lupus erythematosus had significantly higher levels of endothelial PAS domain-containing protein 1 and ghrelin compared with healthy controls (p<0.001). Endothelial PAS domain-containing protein 1 showed a moderate positive correlation with right ventricular systolic motion (p=0.007). Patients with systemic lupus erythematosus and a higher disease activity had elevated endothelial PAS domain-containing protein 1 levels, particularly those with positive antiphospholipid antibodies (p<0.001). No significant correlation was found between ghrelin levels and right ventricular function. Receiver operating characteristic curve analysis identified cutoff values for endothelial PAS domain-containing protein 1 (≥1.871) and ghrelin (≥360.50) with moderate sensitivity and specificity for predicting systemic lupus erythematosus.
conclusionThis study suggests that endothelial PAS domain-containing protein 1 and ghrelin may play important roles in the pathophysiology of right ventricular dysfunction in systemic lupus erythematosus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.